- Home
- FLNG vs SYRE Comparison
FLNG vs SYRE Comparison
Compare FLNG & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNG
- SYRE
- Stock Information
- Founded
- FLNG 2006
- SYRE 2013
- Country
- FLNG Bermuda
- SYRE United States
- Employees
- FLNG N/A
- SYRE N/A
- Industry
- FLNG Marine Transportation
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- FLNG Consumer Discretionary
- SYRE Health Care
- Exchange
- FLNG Nasdaq
- SYRE Nasdaq
- Market Cap
- FLNG 1.3B
- SYRE 1.1B
- IPO Year
- FLNG N/A
- SYRE 2016
- Fundamental
- Price
- FLNG $25.26
- SYRE $15.65
- Analyst Decision
- FLNG Hold
- SYRE Buy
- Analyst Count
- FLNG 1
- SYRE 5
- Target Price
- FLNG $23.00
- SYRE $55.00
- AVG Volume (30 Days)
- FLNG 537.5K
- SYRE 455.6K
- Earning Date
- FLNG 11-11-2025
- SYRE 11-06-2025
- Dividend Yield
- FLNG 11.87%
- SYRE N/A
- EPS Growth
- FLNG N/A
- SYRE N/A
- EPS
- FLNG 1.83
- SYRE N/A
- Revenue
- FLNG $355,837,000.00
- SYRE N/A
- Revenue This Year
- FLNG N/A
- SYRE N/A
- Revenue Next Year
- FLNG $3.41
- SYRE N/A
- P/E Ratio
- FLNG $13.92
- SYRE N/A
- Revenue Growth
- FLNG N/A
- SYRE N/A
- 52 Week Low
- FLNG $19.46
- SYRE $10.91
- 52 Week High
- FLNG $27.67
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- FLNG 44.33
- SYRE 40.69
- Support Level
- FLNG $24.65
- SYRE $15.80
- Resistance Level
- FLNG $26.04
- SYRE $17.58
- Average True Range (ATR)
- FLNG 0.56
- SYRE 0.75
- MACD
- FLNG -0.27
- SYRE -0.12
- Stochastic Oscillator
- FLNG 20.20
- SYRE 0.52
About FLNG FLEX LNG Ltd.
Flex LNG Ltd is an LNG shipping company with a fleet of next-generation LNG carriers with large cargo capacity. The fleet consists of thirteen modern LNG ships, ten existing and three under construction for delivery. All LNG carriers are equipped with slow-speed, two-stroke engines MEGI or X-DF propulsion which will provide Charterers with tonnage offering advantages in form of reduced fuel consumption and lowered boil-off rates.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.